DDInter458 DDInter1658
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cyclosporine {u} (Compound) treats {v} (Disease) focal segmental glomerulosclerosis
Cyclosporine {u} (Compound) binds {v} (Gene) SLC10A2
Cyclosporine {u} (Compound) upregulates {v} (Gene) IFRD1
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Cyclosporine {u} (Compound) downregulates {v} (Gene) CENPF
Cyclosporine {u} (Compound) causes {v} (Side Effect) Injury
Cyclosporine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPIB
Cyclosporine (Compound) treats focal segmental glomerulosclerosis (Disease)
Cyclosporine (Compound) binds SLC10A2 (Gene)
Cyclosporine (Compound) upregulates IFRD1 (Gene)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Cyclosporine (Compound) downregulates CENPF (Gene)
Cyclosporine (Compound) causes Injury (Side Effect)
Cyclosporine (Compound) binds PPIB (Gene) and Cyclosporine (Compound) upregulates PPIB (Gene)